Hepcidin as a new biomarker for detecting autologous blood transfusion.

Détails

ID Serval
serval:BIB_2DDE07BF29A7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Hepcidin as a new biomarker for detecting autologous blood transfusion.
Périodique
American Journal of Hematology
Auteur(s)
Leuenberger N., Barras L., Nicoli R., Robinson N., Baume N., Lion N., Barelli S., Tissot J.D., Saugy M.
ISSN
1096-8652 (Electronic)
ISSN-L
0361-8609
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
91
Numéro
5
Pages
467-472
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
Autologous blood transfusion (ABT) is an efficient way to increase sport performance. It is also the most challenging doping method to detect. At present, individual follow-up of haematological variables via the athlete biological passport (ABP) is used to detect it. Quantification of a novel hepatic peptide called hepcidin may be a new alternative to detect ABT. In this prospective clinical trial, healthy subjects received a saline injection for the control phase, after which they donated blood that was stored and then transfused 36 days later. The impact of ABT on hepcidin as well as haematological parameters, iron metabolism, and inflammation markers was investigated. Blood transfusion had a particularly marked effect on hepcidin concentrations compared to the other biomarkers, which included haematological variables. Hepcidin concentrations increased significantly: 12 hr and 1 day after blood reinfusion, these concentrations rose by seven- and fourfold, respectively. No significant change was observed in the control phase. Hepcidin quantification is a cost-effective strategy that could be used in an "ironomics" strategy to improve the detection of ABT. Am. J. Hematol. 91:467-472, 2016. © 2016 Wiley Periodicals, Inc.
Pubmed
Web of science
Création de la notice
09/02/2016 14:06
Dernière modification de la notice
20/08/2019 14:12
Données d'usage